MedStar Georgetown treats first patients with MEVION S250i proton therapy

MedStar Georgetown treats first patients with MEVION S250i proton therapy

by Lauren Dubinsky, Senior Reporter | April 05, 2018
Rad Oncology Proton Therapy
The MEVION S250i Proton Therapy System
with HYPERSCAN Pencil Beam Scanning
at MedStar Georgetown University Hospital
MedStar Georgetown University Hospital in Washington, D.C. recently become the first to treat a patient with the MEVION S250i Proton Therapy System.

“The system can be used for a wide variety of complex tumors, such as central nervous system, base of skull, lung, GI, GU, breast and liver to name a few,” Skip Rosenthal, vice president of clinical systems at Mevion, told HCB News.

The system at MedStar Georgetown is equipped with the company’s HYPERSCAN pencil beam scanning technology, enabling clinicians to deliver conformal fields faster and more accurately than standard proton therapy systems.

Servicing GE/Siemens Nuclear Medicine equipment with OEM trained engineers

Numed, a well established company in business since 1975 provides a wide range of service options including time & material service, PM only contracts, full service contracts, labor only contracts & system relocation. Call 800 96 Numed for more info.

“HYPERSCAN Pencil Beam Scanning is a type of conformal proton therapy which is ideal for treating solid cancer tumors in close proximity to critical organs including indications where motion creates additional challenges,” said Rosenthal.

The MEVION S250i also features the Adaptive Aperture proton multi-leaf collimator, which sharpens lateral dose gradients. It’s designed to protect sensitive organs at every energy layer of treatment.

At MedStar Georgetown, the system was integrated into the hospital as part of a renovation to the existing cancer entrance. Other proton centers have typically constructed standalone facilities, but this system is small enough to fit into existing radiation oncology departments.

The MEVION S250i system is actively being installed in centers throughout the U.S. and Europe — two of which are expected to be treating patients by the end of this year.

You Must Be Logged In To Post A Comment